Clinical utility of high-throughput glycome analysis in patients with pancreatic cancer

Kazuhiro Nouso, Maho Amano, Yoichi M. Ito, Koji Miyahara, Yuki Morimoto, Hironari Katou, Koichiro Tsutsumi, Takeshi Tomoda, Naoki Yamamoto, Shinichiro Nakamura, Sayo Kobayashi, Kenji Kuwaki, Hiroaki Hagihara, Hideki Ohnishi, Yasuhiro Miyake, Fusao Ikeda, Hidenori Shiraha, Akinobu Takaki, Taku Nakahara, Shin Ichiro NishimuraKazuhide Yamamoto

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Background: Most of the glycan changes reported in cancers were based on the examinations of a small number of patients or particular proteins. The aim of this study was to determine the changes of the serum N-glycan profile comprehensively in a large number of pancreatic cancer patients and investigate its clinical utility. Methods: Glycan levels in the serum of 92 pancreatic cancer patients and 243 healthy volunteers (HLT) were examined by comprehensive quantitative high-throughput glycome analysis and were compared with clinical parameters. Results: Out of 66 glycans detected, 15 were differentially expressed in pancreatic cancer, and 10 out of the 15 glycans were significantly up-regulated in cases with distant metastasis. There was a clear increase in overall expression of serum glycans, especially highly-branched glycans with fucose moieties, in pancreatic cancer. Among these 15 glycans, a tri-antennary complex type glycan (m/z 3195) showed the highest area under the receiver operating characteristic curve (AUROC = 0.799) for the diagnosis of pancreatic cancer. The ratio of pairs of glycans on the same path of the biosynthesis pathway (m/z 3195/1914) was found to be significantly higher in pancreatic cancer than in HLT (median = 1.11 and 0.41, respectively; p <0.0001, AUROC = 0.831). For this pair ratio, the hazard ratio for survival (2.60, 95 % CI = 1.44-4.79) was higher than that of any single glycan and 1-year survival of patients with a high and low ratio was 36.9 and 69.2 %, respectively, (p = 0.001). Conclusions: Comprehensive glycome analysis can be used to know the presence of pancreatic cancer, distant metastasis, and patient prognosis, simultaneously.

Original languageEnglish
Pages (from-to)1171-1179
Number of pages9
JournalJournal of Gastroenterology
Volume48
Issue number10
DOIs
Publication statusPublished - Oct 2013

Fingerprint

Pancreatic Neoplasms
Polysaccharides
Healthy Volunteers
Serum
Neoplasm Metastasis
Fucose
Survival
ROC Curve

Keywords

  • Diagnosis
  • N-glycan
  • Pancreatic cancer

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Clinical utility of high-throughput glycome analysis in patients with pancreatic cancer. / Nouso, Kazuhiro; Amano, Maho; Ito, Yoichi M.; Miyahara, Koji; Morimoto, Yuki; Katou, Hironari; Tsutsumi, Koichiro; Tomoda, Takeshi; Yamamoto, Naoki; Nakamura, Shinichiro; Kobayashi, Sayo; Kuwaki, Kenji; Hagihara, Hiroaki; Ohnishi, Hideki; Miyake, Yasuhiro; Ikeda, Fusao; Shiraha, Hidenori; Takaki, Akinobu; Nakahara, Taku; Nishimura, Shin Ichiro; Yamamoto, Kazuhide.

In: Journal of Gastroenterology, Vol. 48, No. 10, 10.2013, p. 1171-1179.

Research output: Contribution to journalArticle

Nouso, K, Amano, M, Ito, YM, Miyahara, K, Morimoto, Y, Katou, H, Tsutsumi, K, Tomoda, T, Yamamoto, N, Nakamura, S, Kobayashi, S, Kuwaki, K, Hagihara, H, Ohnishi, H, Miyake, Y, Ikeda, F, Shiraha, H, Takaki, A, Nakahara, T, Nishimura, SI & Yamamoto, K 2013, 'Clinical utility of high-throughput glycome analysis in patients with pancreatic cancer', Journal of Gastroenterology, vol. 48, no. 10, pp. 1171-1179. https://doi.org/10.1007/s00535-012-0732-7
Nouso, Kazuhiro ; Amano, Maho ; Ito, Yoichi M. ; Miyahara, Koji ; Morimoto, Yuki ; Katou, Hironari ; Tsutsumi, Koichiro ; Tomoda, Takeshi ; Yamamoto, Naoki ; Nakamura, Shinichiro ; Kobayashi, Sayo ; Kuwaki, Kenji ; Hagihara, Hiroaki ; Ohnishi, Hideki ; Miyake, Yasuhiro ; Ikeda, Fusao ; Shiraha, Hidenori ; Takaki, Akinobu ; Nakahara, Taku ; Nishimura, Shin Ichiro ; Yamamoto, Kazuhide. / Clinical utility of high-throughput glycome analysis in patients with pancreatic cancer. In: Journal of Gastroenterology. 2013 ; Vol. 48, No. 10. pp. 1171-1179.
@article{5cb63e29446e49c3a9327891d12763c9,
title = "Clinical utility of high-throughput glycome analysis in patients with pancreatic cancer",
abstract = "Background: Most of the glycan changes reported in cancers were based on the examinations of a small number of patients or particular proteins. The aim of this study was to determine the changes of the serum N-glycan profile comprehensively in a large number of pancreatic cancer patients and investigate its clinical utility. Methods: Glycan levels in the serum of 92 pancreatic cancer patients and 243 healthy volunteers (HLT) were examined by comprehensive quantitative high-throughput glycome analysis and were compared with clinical parameters. Results: Out of 66 glycans detected, 15 were differentially expressed in pancreatic cancer, and 10 out of the 15 glycans were significantly up-regulated in cases with distant metastasis. There was a clear increase in overall expression of serum glycans, especially highly-branched glycans with fucose moieties, in pancreatic cancer. Among these 15 glycans, a tri-antennary complex type glycan (m/z 3195) showed the highest area under the receiver operating characteristic curve (AUROC = 0.799) for the diagnosis of pancreatic cancer. The ratio of pairs of glycans on the same path of the biosynthesis pathway (m/z 3195/1914) was found to be significantly higher in pancreatic cancer than in HLT (median = 1.11 and 0.41, respectively; p <0.0001, AUROC = 0.831). For this pair ratio, the hazard ratio for survival (2.60, 95 {\%} CI = 1.44-4.79) was higher than that of any single glycan and 1-year survival of patients with a high and low ratio was 36.9 and 69.2 {\%}, respectively, (p = 0.001). Conclusions: Comprehensive glycome analysis can be used to know the presence of pancreatic cancer, distant metastasis, and patient prognosis, simultaneously.",
keywords = "Diagnosis, N-glycan, Pancreatic cancer",
author = "Kazuhiro Nouso and Maho Amano and Ito, {Yoichi M.} and Koji Miyahara and Yuki Morimoto and Hironari Katou and Koichiro Tsutsumi and Takeshi Tomoda and Naoki Yamamoto and Shinichiro Nakamura and Sayo Kobayashi and Kenji Kuwaki and Hiroaki Hagihara and Hideki Ohnishi and Yasuhiro Miyake and Fusao Ikeda and Hidenori Shiraha and Akinobu Takaki and Taku Nakahara and Nishimura, {Shin Ichiro} and Kazuhide Yamamoto",
year = "2013",
month = "10",
doi = "10.1007/s00535-012-0732-7",
language = "English",
volume = "48",
pages = "1171--1179",
journal = "Journal of Gastroenterology",
issn = "0944-1174",
publisher = "Springer Japan",
number = "10",

}

TY - JOUR

T1 - Clinical utility of high-throughput glycome analysis in patients with pancreatic cancer

AU - Nouso, Kazuhiro

AU - Amano, Maho

AU - Ito, Yoichi M.

AU - Miyahara, Koji

AU - Morimoto, Yuki

AU - Katou, Hironari

AU - Tsutsumi, Koichiro

AU - Tomoda, Takeshi

AU - Yamamoto, Naoki

AU - Nakamura, Shinichiro

AU - Kobayashi, Sayo

AU - Kuwaki, Kenji

AU - Hagihara, Hiroaki

AU - Ohnishi, Hideki

AU - Miyake, Yasuhiro

AU - Ikeda, Fusao

AU - Shiraha, Hidenori

AU - Takaki, Akinobu

AU - Nakahara, Taku

AU - Nishimura, Shin Ichiro

AU - Yamamoto, Kazuhide

PY - 2013/10

Y1 - 2013/10

N2 - Background: Most of the glycan changes reported in cancers were based on the examinations of a small number of patients or particular proteins. The aim of this study was to determine the changes of the serum N-glycan profile comprehensively in a large number of pancreatic cancer patients and investigate its clinical utility. Methods: Glycan levels in the serum of 92 pancreatic cancer patients and 243 healthy volunteers (HLT) were examined by comprehensive quantitative high-throughput glycome analysis and were compared with clinical parameters. Results: Out of 66 glycans detected, 15 were differentially expressed in pancreatic cancer, and 10 out of the 15 glycans were significantly up-regulated in cases with distant metastasis. There was a clear increase in overall expression of serum glycans, especially highly-branched glycans with fucose moieties, in pancreatic cancer. Among these 15 glycans, a tri-antennary complex type glycan (m/z 3195) showed the highest area under the receiver operating characteristic curve (AUROC = 0.799) for the diagnosis of pancreatic cancer. The ratio of pairs of glycans on the same path of the biosynthesis pathway (m/z 3195/1914) was found to be significantly higher in pancreatic cancer than in HLT (median = 1.11 and 0.41, respectively; p <0.0001, AUROC = 0.831). For this pair ratio, the hazard ratio for survival (2.60, 95 % CI = 1.44-4.79) was higher than that of any single glycan and 1-year survival of patients with a high and low ratio was 36.9 and 69.2 %, respectively, (p = 0.001). Conclusions: Comprehensive glycome analysis can be used to know the presence of pancreatic cancer, distant metastasis, and patient prognosis, simultaneously.

AB - Background: Most of the glycan changes reported in cancers were based on the examinations of a small number of patients or particular proteins. The aim of this study was to determine the changes of the serum N-glycan profile comprehensively in a large number of pancreatic cancer patients and investigate its clinical utility. Methods: Glycan levels in the serum of 92 pancreatic cancer patients and 243 healthy volunteers (HLT) were examined by comprehensive quantitative high-throughput glycome analysis and were compared with clinical parameters. Results: Out of 66 glycans detected, 15 were differentially expressed in pancreatic cancer, and 10 out of the 15 glycans were significantly up-regulated in cases with distant metastasis. There was a clear increase in overall expression of serum glycans, especially highly-branched glycans with fucose moieties, in pancreatic cancer. Among these 15 glycans, a tri-antennary complex type glycan (m/z 3195) showed the highest area under the receiver operating characteristic curve (AUROC = 0.799) for the diagnosis of pancreatic cancer. The ratio of pairs of glycans on the same path of the biosynthesis pathway (m/z 3195/1914) was found to be significantly higher in pancreatic cancer than in HLT (median = 1.11 and 0.41, respectively; p <0.0001, AUROC = 0.831). For this pair ratio, the hazard ratio for survival (2.60, 95 % CI = 1.44-4.79) was higher than that of any single glycan and 1-year survival of patients with a high and low ratio was 36.9 and 69.2 %, respectively, (p = 0.001). Conclusions: Comprehensive glycome analysis can be used to know the presence of pancreatic cancer, distant metastasis, and patient prognosis, simultaneously.

KW - Diagnosis

KW - N-glycan

KW - Pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=84885038677&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885038677&partnerID=8YFLogxK

U2 - 10.1007/s00535-012-0732-7

DO - 10.1007/s00535-012-0732-7

M3 - Article

C2 - 23307043

AN - SCOPUS:84885038677

VL - 48

SP - 1171

EP - 1179

JO - Journal of Gastroenterology

JF - Journal of Gastroenterology

SN - 0944-1174

IS - 10

ER -